Landmark Cancer Clinical Trials and Real-World Patient Populations: Examining Race and Age Reporting
Background: Concern exists that the clinical trial populations differ from respective cancer populations in terms of their age distribution affecting the generalizability of the results, especially in underrepresented minorities. We hypothesized that the clinical trials that do not report race are l...
Guardado en:
Autores principales: | Thejus Jayakrishnan, Sonikpreet Aulakh, Mizba Baksh, Kianna Nguyen, Meghna Ailawadhi, Ayesha Samreen, Ricardo Parrondo, Taimur Sher, Vivek Roy, Rami Manochakian, Aneel Paulus, Asher Chanan-Khan, Sikander Ailawadhi |
---|---|
Formato: | article |
Lenguaje: | EN |
Publicado: |
MDPI AG
2021
|
Materias: | |
Acceso en línea: | https://doaj.org/article/4902baa6ea224b818c6a583586ed5b2c |
Etiquetas: |
Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!
|
Ejemplares similares
-
Role of Immune Checkpoint Inhibitor Therapy in Advanced EGFR-Mutant Non-Small Cell Lung Cancer
por: Nathaniel Wiest, et al.
Publicado: (2021) -
Robotic Pelvic Exenteration for Gynecologic Malignancies, Anatomic Landmarks, and Surgical Steps: A Systematic Review
por: Stefano Cianci, et al.
Publicado: (2021) -
Immunotherapy in Non-Small Cell Lung Cancer With Actionable Mutations Other Than EGFR
por: Karan Seegobin, et al.
Publicado: (2021) -
The Race of CAR Therapies: CAR-NK Cells for Fighting B-Cell Hematological Cancers
por: Lara Herrera, et al.
Publicado: (2021) -
Landmarks: Soering's Legacy
por: Hemme Battjes
Publicado: (2008)